UBS Raises Price Target for CVS Health (NYSE:CVS) Amid Strong Performance

• UBS has increased its price target for CVS Health, projecting a 13.12% potential upside.
• CVS Health stock has recently outperformed the S&P 500 and the Zacks Medical Services industry.
• The company is expanding services, including pet prescriptions, and maintains a strong market capitalization with positive future earnings expectations.

CVS Health (NYSE:CVS) is a major player in the healthcare sector. It operates a large chain of drugstores and also manages pharmacy benefits for clients. Recently, CVS expanded its services by offering common prescription medications for pets at its approximately 9,000 pharmacy locations across the country.

An analyst at UBS shows confidence in the company's direction. They recently increased their price target for CVS to $122.00 from a previous target of $115.00. A price target is an analyst's estimate of a stock's future value. This new target suggests a potential upside of about 13.12% from its price of $107.85 at the time.

This positive analyst view aligns with the CVS stock's recent performance. As highlighted by Zacks.com, shares of CVS have returned 6.10% over the past month. This gain is much higher than the S&P 500 composite's 0.40% change and the Zacks Medical Services industry's 4.90% gain over the same time.

The CVS stock is currently trading near its 52-week high. Its price has ranged from a low of $58.99 to a high of $110.68 over the past year. CVS has a market capitalization of approximately $138.17 billion. This large number reflects the total market value of all its outstanding shares.

Investors are looking ahead to the CVS Health earnings report on August 5, 2026. The company is expected to report an Earnings Per Share (EPS) of $1.87, a 3.31% increase from last year. Projected quarterly revenue is $100.18 billion, which would be a 1.28% rise from the year-ago period.